This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
5 ETF Areas for Investors to Consider Amid the September Slump
by Sweta Jaiswal, FRM
Amid the market uncertainty, we have highlighted some ETF areas that can be good investment options for market participants to combat the September chaos.
Climb the "Wall of Worry" With These ETFs
by Sweta Killa
A myriad of hurdles has continued to kept investors jittery and resulted in a flight to defensive sectors like utilities, real estate, healthcare and consumer staples.
Time for Pharma and Healthcare ETFs?
by Sanghamitra Saha
The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales
2 Sector ETFs Hovering Around All-Time Highs
by Sanghamitra Saha
The U.S. economic backdrop and investors' sentiments have remained mixed in recent weeks.
Healthcare ETFs in Focus as Q2 Earnings Unfold
by Sweta Killa
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.
JNJ Beats on Q2 Earnings, Ups View: ETFs to Buy
by Sweta Killa
The company recorded 164 million in COVID-19 vaccine sales in the second quarter, up 64% from the first, and aims to fetch $2.5 billion in sales by the end of the year.
UnitedHealth's Solid Q2 Earnings Put These ETFs in Focus
by Sweta Killa
UnitedHealth reported better-than-expected second-quarter 2021 results, breezing past the Zacks Consensus Estimate for both earnings and revenues.
Healthcare ETFs on Radar As Q1 Earnings Unfold
by Sweta Killa
Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.
Healthcare ETFs in Focus Post JNJ's Q1 Earnings Results
by Sweta Killa
Johnson & Johnson (JNJ) continued its long streak of earnings beat and outpaced revenue estimates. However, the company tightened its full-year guidance.
Healthcare ETFs to Gain on UnitedHealth's Strong Q1 Earnings
by Sweta Killa
UnitedHealth Group (UNH) reported better-than-expected first-quarter 2021 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues. It also lifted its full-year earnings outlook.